Pomerantz Law Firm Investigates Compass Therapeutics Over Alleged Securities Fraud
Compass Therapeutics (NASDAQ: CMPX) announced mixed results from a phase 2/3 study of its drug tovecimig, leading to a 64.41% drop in its stock price. Pomerantz LLP is investigating potential securities fraud by the company and its officers. The study met one secondary endpoint but missed another, raising concerns about the company's disclosures.
Tickers: $CMPX
Topics: class action clinical trial results pharmaceutical company securities fraud stock price drop